Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Galapagos
Sponsor

Galapagos

Belgium Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium

About the sponsor

Galapagos focuses on relapsed or refractory blood cancers, with studies in multiple myeloma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and B-cell non-Hodgkin lymphoma. The portfolio includes CAR T-cell therapy and anti-CD19 or anti-BCMA approaches aimed at difficult-to-treat malignant B-cell disorders.

  • Relapsed/refractory multiple myeloma
  • Chronic lymphocytic leukemia and small lymphocytic lymphoma
  • B-cell non-Hodgkin lymphoma
  • CAR T-cell therapies

These oncology programs span multiple active sites across several countries, reflecting a strong interest in advanced cellular immunotherapy for resistant haematologic disease.

About Specializations

Galapagos runs clinical trials in conditions such as Chronic lymphocytic leukaemia, B-cell small lymphocytic lymphoma, Systemic lupus erythematosus, Plasma cell myeloma refractory, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

7 clinical trials

Chronic lymphocytic leukaemia+1

Recruiting

Long-Term Safety Study of BCMACP03, BCN-CP01, and 19CP02 for Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, CLL, SLL, or Multiple Myeloma

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BCMACP03
  • Sponsor:Galapagos

Systemic lupus erythematosus

Not recruiting

Study of GLPG3667 for Adults with Active Systemic Lupus Erythematosus

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:GLPG3667 fumarate
  • Sponsor:Galapagos

Systemic lupus erythematosus

Not recruiting

Evaluation of safety and efficacy of 19CP02 combined with cyclophosphamide and fludarabine phosphate in adults with treatment‑refractory active systemic lupus erythematosus

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Cyclophosphamide
  • Sponsor:Galapagos

Chronic lymphocytic leukaemia+1

Not recruiting

Study on the Safety and Effectiveness of BCN-CP01 for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:Galapagos

Study on the Safety and Effectiveness of 19CP02 for Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Not recruiting
InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:19Cp02
  • Sponsor:Galapagos

Plasma cell myeloma refractory

Not recruiting

Study on the Safety and Effectiveness of BCMACP03 for Patients with Relapsed or Refractory Multiple Myeloma

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BCMACP03
  • Sponsor:Galapagos

Dermatomyositis

Not recruiting

Study on the Effects of GLPG3667 for Adults with Dermatomyositis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:GLPG3667 fumarate
  • Sponsor:Galapagos

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.